Loading...
Market
Clinical benefits of injectable Leqembi in the first year
4
Resolution / Starting Odds
Significantly better than existing treatments • 25%
Marginally better than existing treatments • 25%
Equivalent to existing treatments • 25%
Underperforms existing treatments • 25%
Clinical study reports, medical journals, and health news outlets
Story
Eisai and Biogen Begin Rolling BLA for Subcutaneous, Injectable Alzheimer's Drug Leqembi
May 15, 2024, 04:15 AM
Eisai and Biogen have initiated a rolling Biologics License Application (BLA) to the U.S. FDA for a subcutaneous, injectable version of their Alzheimer's drug, Leqembi. This submission, which had been delayed due to procedural issues, aims to provide a maintenance dosing option for early Alzheimer's disease. The application is being processed under the FDA's Fast Track status, which is designed to expedite the review of drugs that treat serious conditions and fill an unmet medical need.
View original story
Similar markets
Highly positive outcomes • 25%
Moderately positive outcomes • 25%
Neutral outcomes • 25%
Negative outcomes • 25%
Significant stock price increase (over 15%) • 25%
Moderate stock price increase (5-15%) • 25%
Little to no change (0-5%) • 25%
Stock price decrease • 25%
Approved in US and EU • 25%
Approved only in US • 25%
Approved only in EU • 25%
Not approved in US or EU • 25%
More effective than existing treatments • 25%
Equally effective as existing treatments • 25%
Less effective than existing treatments • 25%
Ineffective • 25%
Donanemab surpasses Leqembi in market share • 33%
Donanemab equals Leqembi in market share • 33%
Leqembi remains ahead in market share • 33%
Significant improvement • 33%
Moderate improvement • 34%
No improvement or worsening • 33%
Exceeds market expectations • 33%
Meets market expectations • 34%
Falls below market expectations • 33%
High adoption and positive reception • 25%
Moderate adoption and mixed reviews • 25%
Low adoption and negative reception • 25%
Other outcomes • 25%